Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

Cheap OEM Software
  

Search in our Online Store
R&D Licensing
Filter     Order     Display # 
Date Item Title
04 May 2007 CyDex Licenses Captisol(R) to Sunesis Pharmaceuticals for Oncology Drug Candidate
01 May 2007 Sangamo BioSciences Announces Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production
01 May 2007 Cardiome Announces In-Licensing Agreement with Eli Lilly and Company
28 Apr 2007 Kyowa Hakko in-licenses ARQ 197, an anticancer agent in clinical development, from the US company ArQule.
27 Apr 2007 Royalty Pharma and InNexus Biotechnology Announce Agreement Regarding the Purchase of Royalty Rights Based on DXL(TM) Antibody Products
27 Apr 2007 SciClone Acquires Clinical-Stage Pancreatic Cancer Compound
27 Apr 2007 Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds
27 Apr 2007 Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds
25 Apr 2007 Neuromed Licenses Phase 3 Chronic Pain Product from ALZA Corporation
24 Apr 2007 Synosia Therapeutics Announces Second Major Pharmaceutical Deal
24 Apr 2007 KaloBios Licenses Humaneering(TM) Technology to Major Pharmaceutical Company
20 Apr 2007 Novacea Acquires Worldwide Development and Commercialization Rights for Its Oncology Candidate AQ4N
19 Apr 2007 Viragen Announces European Multiferon(R) Licensing Agreement
19 Apr 2007 Vasogen and Grupo Ferrer Form Collaboration to Commercialize Celacade(TM) in the European Union
18 Apr 2007 Salix Pharmaceuticals Licenses DIACOL(TM) To Dr. Falk Pharma in Europe
18 Apr 2007 Wockhardt to soon introduce Kelocote to treat scars
18 Apr 2007 DeveloGen and Andromeda, a newly formed wholly-owned subsidiary of Clal Biotechnology Industries, Sign Term Sheet for Asset Purchase Agreement for the DiaPep277(R) Program
14 Apr 2007 Syndax Pharmaceuticals, Inc. Licenses Selective Histone Deacetylase Inhibitor MS-275
13 Apr 2007 Coley Pharmaceutical Group Licenses VaxImmune(TM) to Merck for Use in Vaccine Programs
12 Apr 2007 Roche and Transgene enter partnership on therapeutic vaccines against HPV-mediated diseases
12 Apr 2007 Repligen Licenses Potential Treatment for Friedreich's Ataxia from The Scripps Research Institute
12 Apr 2007 Xanthus Acquires from Johns Hopkins University Exclusive License to Patent Estate Covering FLT3 Pathway as a Target for Treating Autoimmune Diseases
12 Apr 2007 Novosom AG Acquires Exclusive Option for CD40-Targeted Antisense Inhibitors From Isis Pharmaceuticals
05 Apr 2007 AVEO enters into Worldwide License and Development Agreement with Schering-Plough for AV-299, AVEO's Novel Anti-HGF Antibody
05 Apr 2007 pSivida signs A$203 million (US$165 million)
04 Apr 2007 Pharmexa and Affitech enter into an exclusive license agreement to promote Diabody technology
03 Apr 2007 Senetek PLC Grants Paid Up License to Valeant Pharmaceuticals
31 Mar 2007 CanBas and Takeda to Sign the Collaboration Agreement
31 Mar 2007 Takeda to Obtain Development and Commercial Rights
31 Mar 2007 Astellas Licenses Regeneronīs Velocimmune(R) Technology For Discovering Human Monoclonal Antibodies
29 Mar 2007 Samaritan Pharma Partners PII HIV Drug to Pharmaplaz; Upfront Payment $10 Million
29 Mar 2007 MorphoSys and Astellas Enter Antibody Partnership - Deal Seals MorphoSys's Third Japanese Pharmaceutical Alliance
29 Mar 2007 Oxford BioMedica and Sanofi-Aventis Enter Global Licensing Agreement to Develop and Commercialise TroVax for Cancer
28 Mar 2007 Seattle Genetics Announces Extension of Antibody-Drug Conjugate Collaboration with Genentech
27 Mar 2007 Novartis to launch its own branded version of a leading multiple sclerosis therapy through agreement with Bayer Schering Pharma
23 Mar 2007 Cubist Pharmaceuticals Licenses Rights for Development and Commercialization of CUBICIN in Japan to Merck & Co., Inc.
23 Mar 2007 Pain Therapeutics Licenses Biotechnology To Treat Rare Disorder
22 Mar 2007 BioLineRx In-Licenses Novel Peptide for the Treatment of Inflammatory Diseases
20 Mar 2007 Akesis Pharmaceuticals Obtains Exclusive License for Proprietary Clinical Stage Diabetes Therapy from the University of British Columbia
17 Mar 2007 Nippon Shinyaku and Teva terminate HMN-214 License Agreement
17 Mar 2007 Micromet and TRACON Pharmaceuticals Sign Exclusive Worldwide License Agreement to Develop and Commercialize D93, a Humanized Antibody for Cancer Treatment
16 Mar 2007 Emergent BioSolutions Gains Rights To VaxImmune(TM) From Coley Pharmaceutical Group to Expand Its Anthrax Franchise
16 Mar 2007 Trimeris and Roche Amend Research Agreement Covering Next-Generation HIV Fusion Inhibitors
14 Mar 2007 Maxygen Announces End of Co-Development Agreement
14 Mar 2007 Array BioPharma and VentiRx Pharmaceuticals Announce License Agreement
08 Mar 2007 Stemline Expands its Oncology Pipeline with Acquisition of Clinically Active Compound Directed to "Cancer Stem Cell" Target
07 Mar 2007 Clinquest Group and TNO sign licensing agreement on protein for inflammatory disorders
07 Mar 2007 ProNAi and Novosom AG Announce Collaboration to Enable Delivery of DNAi-based Cancer Therapeutics
07 Mar 2007 Kyowa Hakko Kogyo Co., Ltd. Licenses its in-house developed antibody KW-2871 targeting malignant melanoma to Life Science Pharmaceuticals in the US.
07 Mar 2007 Nautilus Biotech and HanAll Pharmaceutical announce license agreement to develop three Nautilus Biotech products in South Korea
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 351 - 400 of 814

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Diabetes Drug Pipeline

Order Now

Brief Report Series

CD40 and CD40L (CD154) Agonists & Antagonists

Order Now

Subscribe La Merie Biologics